Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab

Ricardo Mesquita Camelo, Mariana Michel Barbosa, Maiara Silva Araújo, Roberto Lúcio Muniz, Augusto Afonso Guerra, Brian Godman, Suely Meireles Rezende, Francisco de Assis Acurcio, Antony P. Martin, Juliana Alvares-Teodoro*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)

Abstract

Objective: This study aimed to measure the cost-effectiveness of prophylaxis with emicizumab in PsHAhri on ITI in Brazil. Methods: A cost-effectiveness modeling analysis was used to estimate the costs per PsHAhri on ITI and the number of prevented bleedings from undertaking one intervention (prophylaxis with BpA) over another (prophylaxis with emicizumab), based on the Brazilian Ministry of Health perspective. Costs of ITI with recombinant FVIII, prophylaxis with BpA or emicizumab, and treated bleeding episodes with BpA costs were evaluated for PsHAhri who had ITI success or failure. This study was conducted with the perspective of the Brazilian Ministry of Health (payer). Results: During ITI, prophylaxis with BpA cost US $924 666/PsHAhri/ITI, whereas prophylaxis with emicizumab cost US $488 785/PsHAhri/ITI. During ITI, there was an average of 9.32 bleeding episodes/PsHAhri/ITI when BpA were used as prophylaxis and 0.67 bleeding/PsHAhri/ITI when emicizumab was used. By univariate deterministic sensitivity analysis, emicizumab remained dominant whichever variable was modified. Conclusion: In this study, prophylaxis with emicizumab during ITI is a dominant option compared with prophylaxis with BpA during ITI.

Original languageEnglish
Pages (from-to)31-39
Number of pages9
JournalValue in Health Regional Issues
Volume34
DOIs
Publication statusPublished - Mar 2023

Keywords

  • activated prothrombin complex concentrate
  • bypassing agents
  • cost-effectiveness analysis
  • emicizumab
  • immune tolerance induction
  • prophylaxis
  • recombinant activated factor VII

Fingerprint

Dive into the research topics of 'Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab'. Together they form a unique fingerprint.

Cite this